Navigation Links
Cyclacel Pharmaceuticals to Present Preclinical Data on,Sapacitabine and Seliciclib at AACR

division cycle. Both sapacitabine and its major metabolite, CNDAC, have demonstrated in preclinical studies potent anti-tumor activity in both hematological and solid tumors. Sapacitabine has been administered to approximately 150 patients enrolled in three Phase I clinical trials in solid tumors and a Phase I study in hematological tumors conducted by Dr. Hagop Kantarjian, Professor of Medicine and Chairman of the Leukemia Department at M.D. Anderson Cancer Center (UTMDACC) in Houston, Texas. Based on the results of these studies, Cyclacel plans to initiate Phase II trials of sapacitabine in 2007 to evaluate the drug in both hematological and solid tumors.

About CYC116

CYC116 is an orally-available inhibitor of Aurora kinases A and B and VEGFR2. In December 2006, Cyclacel submitted to FDA an Investigational New Drug (IND) application to begin clinical trials of CYC116. Phase I trials will be conducted at multiple centers in the US evaluating the safety profile of CYC116 as a single agent in patients with both hematological and solid tumors.

Please visit http://www.cyclacel.com/cyc/investors/news/pressreleases/ for additional information on the above highlights.

Note: The Cyclacel logo and Cyclacel(R) are trademarks of Cyclacel Pharmaceuticals, Inc.

Risk Factors

This news release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include statements regarding, among other things, the efficacy, safety, and intended utilization of Cyclacel's product candidates, the conduct and results of future clinical trials, plans regarding regulatory filings, future research and clinical trials and plans regarding partnering activities. Factors that may cause actual results to differ materially include the risk tha
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
2. Cyclacel Pharmaceuticals to Report Sapacitabine Phase I Study Results at the American Society of Clinical Oncology Annual Meeting
3. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
7. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
8. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
9. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
10. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
11. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
Post Your Comments:
(Date:8/27/2014)... BOSTON , Aug. 27, 2014  Columbia Laboratories, ... Company"), a provider of pharmaceutical development, clinical trial manufacturing, ... industry, today announced that it will participate at the ... Investment Conference, to be held in New ... conference at 11:15am on September 9, 2014 at the ...
(Date:8/27/2014)... and NINGBO, China , ... the Ningbo Menovo Pharmaceutical Co., Ltd, ("Menovo") today announced ... development of generic pharmaceuticals, primarily targeting the ... the agreement, Amerigen and Menovo will jointly develop products ... States . Menovo will be responsible for manufacturing ...
(Date:8/27/2014)... 2014 /CNW/ - Covalon Technologies Ltd. (the "Company" or "Covalon") ... financial results for its third quarter of fiscal 2014: ... , Revenue of $1,291,378, a 13% decrease over the ... for the quarter of $240,156 compared to net income of ... For the nine months ended June 30, 2014: ...
Breaking Medicine Technology:Amerigen Pharmaceuticals Limited and the Ningbo Menovo Pharmaceutical Co., Ltd, today announced they had entered into a collaboration agreement regarding the development of generic pharmaceuticals, primarily targeting the United States market 2Covalon Announces Third Quarter Results 2Covalon Announces Third Quarter Results 3
(Date:8/27/2014)... 2014 Taking its popular obstacle race to ... YMCA will host its largest crowd at its ... 13 at YMCA Camp Thunderbird . , ... adult, youth and teams. Within each division, runners will attempt ... limit - for a worthy cause. All proceeds will ...
(Date:8/27/2014)... Today, Zane Benefits, the #1 Online ... for administering a premium reimbursement plan. , According ... compliance is top of mind for employers, health insurance ... insurance and premium reimbursement, there are important compliance considerations ... minute webinar, Zane Benefits President, Rick Lindquist, will cover ...
(Date:8/27/2014)... Skirt Sports , the innovative women’s running ... runner, Kathrine Switzer, most noted for her brave running of ... line of women’s running clothes that unites the history of ... Fearless Movement. , “It is such an honor ... “Kathrine is the original Skirt – she stood strong, ...
(Date:8/27/2014)... steep decline in the use of hormone therapy has ... women suffering in silence with hot flashes, according to ... and colleagues. , In the study published in ... Menopause , the team found that moderate to severe ... are not treated in most women. Women with VMS ...
(Date:8/27/2014)... 28, 2014 BRIC Laparoscopes Market Outlook ... provides key market data on the BRIC Laparoscopes market. ... volume (in units) and average prices (in US dollars) ... and Flexible Tip Video Laparoscopes), Robotic Surgical Systems and ... of advantages to the patient with laparoscopic surgery versus ...
Breaking Medicine News(10 mins):Health News:C2 Survival Racers Go to Extremes to Provide Kids with YMCA Programs 2Health News:Zane Benefits Announces Upcoming Webinar on Compliance 2Health News:Skirt Sports Launches Clothing Line with Legendary Runner Kathrine Switzer 2Health News:The high cost of hot flashes: Millions in lost wages preventable 2Health News:Laparoscopes & Endoscopic Reprocessors Market in BRIC (Brazil, Russia, India & China) to 2020 Report Available at RnRMarketResearch.com 2Health News:Laparoscopes & Endoscopic Reprocessors Market in BRIC (Brazil, Russia, India & China) to 2020 Report Available at RnRMarketResearch.com 3Health News:Laparoscopes & Endoscopic Reprocessors Market in BRIC (Brazil, Russia, India & China) to 2020 Report Available at RnRMarketResearch.com 4
... Inc. (Nasdaq: VNUS ), a leading provider of ... disease, today,announced that it presented at the William Blair ... on October 3, 2007, at the New York,Palace Hotel ... the VNUS presentation webcast is available on the,corporate website ...
... SAN DIEGO, Oct. 3 Anadys Pharmaceuticals,Inc. (Nasdaq: ... BIO,InvestorForum 2007 on Wednesday, October 10, 2007, at 11:45 ... at The Palace Hotel in San,Francisco. Steve Worland, ... will present an overview of Anadys and an update ...
... A new Web site from Northwood,Health Systems has ... a five-year development effort in partnership with the best,Web ... perfect the,application of Web site technology," Northwood President and ... http://www.NorthwoodHealth.com, offers more than 1,000 accredited,continuing education courses ...
... NORCROSS, Ga., Oct. 3 Immucor, Inc. (Nasdaq:,BLUD), ... to,the blood transfusion industry, today reported financial results ... Revenue for the fiscal first quarter was ... in the same period last year. Of the ...
... Oct. 3 The patent lawsuit,by VNUS(R) Medical Technologies, ... Diomed, AngioDynamics and Vascular Solutions,is set to proceed to ... by both sides. In its motions VNUS had asked ... infringed the VNUS patents,while the defendants countered with their ...
... will work, experts say , WEDNESDAY, Oct. 3 (HealthDay ... help doctors determine the best chemotherapy for patients, U.S. ... tumors would be most likely to respond to standard ... has traditionally been a second-line therapy, based on gene ...
Cached Medicine News:Health News:Anadys Pharmaceuticals to Present at BIO InvestorForum 2007 2Health News:Immucor Announces Record Fiscal First Quarter Revenues 2Health News:Immucor Announces Record Fiscal First Quarter Revenues 3Health News:Immucor Announces Record Fiscal First Quarter Revenues 4Health News:Immucor Announces Record Fiscal First Quarter Revenues 5Health News:Immucor Announces Record Fiscal First Quarter Revenues 6Health News:Immucor Announces Record Fiscal First Quarter Revenues 7Health News:Immucor Announces Record Fiscal First Quarter Revenues 8Health News:VNUS Medical's Patent Lawsuit Against Laser Competitors to Proceed to Trial 2Health News:VNUS Medical's Patent Lawsuit Against Laser Competitors to Proceed to Trial 3Health News:Gene Tests Match Up Lung Tumors, Best Treatment 2
... Designs ROM post-operative knee braces are designed ... rehabilitation. , ,Adjustable and versatile, ROM ... for health care professionals. The braces are ... feature quick dial combination hinges that allow ...
... Neuroprene™ soft supports are a convenient, ... proprioceptive taping for common orthopedic conditions/instabilities. ... provide specific compression and lateral to ... (proprioceptors) in the skin and soft ...
... The Deluxe Heavy Duty Drop Lock Post Operative ... pin hinge with a spring loaded drop lock ... arms and contoured plates prevent the brace from ... a tibial offset for anatomical alignment that controls ...
... might just be the world's most versatile ... support, post-op/rehab support, or both, Flex is ... Accutrac™ ROM hinges control flexion and extension ... durability while being heat-moldable to accommodate changes ...
Medicine Products: